Success Metrics

Clinical Success Rate

50.0%

Based on 2 completed trials

Completion Rate

50%(2/4)

Active Trials

4(40%)

Results Posted

50%(1 trials)

Terminated

2(20%)

Phase Distribution

Ph phase_1

80%

Ph phase_3

20%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution10 total trials

Phase 1Safety & dosage

8(80.0%)

Phase 3Large-scale testing

2(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

40.0%

2 of 5 finished

Non-Completion Rate

60.0%

3 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Completed(2)

Terminated(3)

Other(1)

Detailed Status

Active, not recruiting4

Terminated2

Completed2

Withdrawn1

unknown1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

50.0%

Most Advanced

Phase 3

Trials by Phase

Phase 18 (80.0%)

Phase 32 (20.0%)

Trials by Status

terminated220%

completed220%

withdrawn110%

unknown110%

active_not_recruiting440%

Recent Activity

4 active trials

Showing 5 of 10

active_not_recruitingphase_3

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

NCT04793958

active_not_recruitingphase_1

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

NCT05722327

terminatedphase_1

A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

NCT05578092

active_not_recruitingphase_1

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

NCT03785249

withdrawnphase_1

Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

NCT05634525

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT04793958Phase 3

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Active Not Recruiting

NCT05722327Phase 1

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

Active Not Recruiting

NCT05578092Phase 1

A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Terminated

NCT03785249Phase 1

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Active Not Recruiting

NCT05634525Phase 1

Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients

Withdrawn

NCT04330664Phase 1

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Completed

NCT05178888Phase 1

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

Completed

NCT04685135Phase 3

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Active Not Recruiting

NCT04975256Phase 1

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

Terminated

NCT05263986Phase 1

The Clinical Trial to Evaluate the Pharmacokinetics and Safety of MRTX849 in Patients With Advanced Solid Tumors

Unknown

All 10 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 10